Detalles de la búsqueda
1.
Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-286567
2.
SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-486403
3.
Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-206847
4.
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-495677
5.
Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-194639
6.
Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22275056
7.
Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-481107
8.
VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-479007
9.
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-469776
10.
An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-459408
11.
Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21250325
12.
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-428097
13.
Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-333278
14.
Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-286948
15.
An S1 subunit vaccine and combination adjuvant (COVAC-1) elicits robust protection against SARS-CoV-2 challenge in African green monkeys
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-496375
16.
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-473679
17.
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-473317
18.
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22273967
19.
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21263532
20.
Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-436337